MEK inhibitors also determine modest benefits in terms of PFS for melanoma patients whose tumors carry missense mutations in NRAS (occurring in about 20% of melanoma cases) [37,38,39,40,41]. This evidence concerns the gene MAP2K7 and melanoma.